Loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma: long-term efficacy and safety from the phase II LOTIS-2 study

Overview of attention for article published in Haematologica, August 2023

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (90th percentile)
High Attention Score compared to outputs of the same age and source (86th percentile)

Mentioned by

news: 1 news outlet
twitter: 10 X users

reddit: 1 Redditor
guideline: 2 clinical guideline sources

Readers on

mendeley: 54 Mendeley

So far, Altmetric has seen 11 X posts from 10 X users, with an upper bound of 50,207 followers.

RT @Haematologica: Read here the updated efficacy and safety analyses from the LOTIS-2 trial studying #Loncastuximab_tesirine (Lonca) as si…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 7 additional X posts.